TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27

Table 1

The relationship between TDO2 expression and clinicopathological features in 116 patients with primary HCC.

Features	Total	TDO2 expression		value
		Normal expression	Low expression
Sex
Male	95	43	52	0.324
Female	21	12	9
Age (years)
≤50	52	23	31	0.254
>50	64	34	30
ALT
<70	106	49	57	0.615
≥70	10	6	4
AST
<70	101	47	54	0.830
≥70	15	8	7
Serum AFP (ng/ml)
<400	62	25	37	0.101
≥400	54	30	24
Tumor size (cm)
≤5	39	26	13	0.011
>5	77	32	45
Tumor number
Single	90	59	41	0.127
Multiple	26	11	15
BCLC stage
0+A	75	48	27	0.019
B+C	41	17	24
TNM stage
I + II	86	46	40	0.027
III + IV	30	9	21
Differentiation
Well/moderate	73	40	33	0.038
Poor	43	15	28
Vascular invasion
Yes	23	7	16	0.069
No	93	48	45
Tumor capsule
Absent	55	26	29	0.977
Present	61	29	32
Recurrence
Yes	58	22	36	0.041
No	58	33	25